Fig. 7
From: Anti-VEGF therapy prevents Müller intracellular edema by decreasing VEGF-A in diabetic retinopathy
Changes in mRNA and protein levels of Kir4.1 and AQP4 in glyoxal-treated rMC-1 cells with or without ranibizumab. The (a) mRNA and (b) protein level of Kir4.1 in glyoxal-treated rMC-1 cells with or without ranibizumab. c Immunofluorescence of Kir4.1 in rMC-1 cells. The (d) mRNA and (e) protein level of AQP4 in glyoxal-treated rMC-1 cells with or without ranibizumab. f Immunofluorescence of AQP4 in rMC-1 cells. Data are expressed as mean ± SE (n = 8 in [a, d], n = 4 in [b, e], *P < 0.05). N: normal control; G: rMC-1 cells treated with 1 mM glyoxal; G + R: rMC-1 cells treated with glyoxal and ranibizumab. Scale bar: 10 μm